Covid-19 Research

Review Article

Therapeutic Strategies in Acute Myeloid Leukemia: Current Advances and Future Directions

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Review Article
Subject Medicine Group
OCLC JBRES Record
Huan Zhang, Shijie Zhang and Jingxin Zhang*
Issue: Volume7-Issue4
Pages: 1-13
Received: 2026-04-15
Accepted: 2026-04-21
Published: 2026-04-22

Abstract

Acute Myeloid Leukemia (AML) is a clinically aggressive and molecularly heterogeneous hematologic malignancy characterized by poor long-term outcomes, largely due to high rates of relapse and therapeutic resistance. For decades, standard treatment has relied on cytotoxic chemotherapy and allogeneic hematopoietic stem cell transplantation; however, these approaches are limited by toxicity and incomplete disease eradication. Advances in genomic and molecular profiling have substantially reshaped the therapeutic landscape, enabling the development of targeted agents directed against key oncogenic drivers, including FLT3 and IDH1/2 mutations, as well as the anti-apoptotic protein BCL-2. These therapies, often used in combination with hypomethylating agents, have improved response rates, particularly in older or unfit patients. In parallel, immunotherapeutic strategies, such as antibody–drug conjugates, bispecific T-cell engagers, and cellular therapies, have been explored, although their efficacy in AML remains constrained by antigen heterogeneity and an immunosuppressive bone marrow microenvironment. Importantly, durable responses are frequently undermined by resistance mechanisms involving leukemia stem cell persistence, clonal evolution, metabolic reprogramming, and niche-mediated protection. Emerging therapeutic strategies emphasize rational combination regimens, targeting metabolic dependencies, and the integration of precision medicine approaches guided by multi-omics profiling and minimal residual disease assessment. In this review, we provide an integrated overview of current therapeutic strategies in AML, with a particular focus on mechanistic insights, resistance pathways, and future directions for improving clinical outcomes.

FullText HTML FullText PDF DOI: 10.37871/jbres2294 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2026 Zhang J, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Zhang H, Zhang S, Zhang J. Therapeutic Strategies in Acute Myeloid Leukemia: Current Advances and Future Directions. J Biomed Res Environ Sci. 2026 Apr 22; 7(4): 13. Doi: 10.37872/jbres2294

Subject area(s)

HematologyOncologyPharmacologyBlood Disorders

References

  1. Gilbert JS, Milano F. Conditioning for acute myeloid leukemia: looking beyond intensity. Haematologica. 2026 Apr 9 [Epub ahead of print]. doi:10.3324/haematol.2026.300787. PMID:41952631.
  2. Zhang H, Zhang J. Comprehensive omics profiling in acute myeloid leukemia: from molecular landscape to clinical translation. Curr Proteomics. 2025;22(3):100028. doi:10.1016/j.curpro.2025.100028.
  3. Chen P, Cao J, Chen L, Gao G, Xu Y, Jia P, et al. Prognostic value of an eighteen-gene panel in acute myeloid leukemia by analyzing TARGET and TCGA databases. Cancer Biomark. 2023;36(4):287-298. doi:10.3233/CBM-220179. PMID:36938728.
  4. Shaikh MR, Singh B, Halder R, Singh R, Shaikh MR, Agarwal N, et al. FLAG-based vs standard 3+7 induction therapy in treatment-naïve acute myeloid leukemia: time to think beyond anthracyclines. Leuk Res. 2023;132:107346. Epub 2023 Jun 28. doi:10.1016/j.leukres.2023.107346. PMID:37467566.
  5. Shimomura Y, Komukai S, Kitamura T, Sobue T, Yamasaki S, Kondo T, et al. The optimal conditioning intensity of stem cell transplantation for acute myeloid leukemia in complete remission. Ann Hematol. 2026;105(4):124. Epub 2026 Feb 19. doi:10.1007/s00277-026-06881-w. PMID:41711974; PMCID:PMC12920725.
  6. Cao S, Wang Q, Zhu G. From chemotherapy to targeted therapy: unraveling resistance in acute myeloid leukemia through genetic and non-genetic insights. Int J Mol Sci. 2025;26(9):4005. Epub 2025 Apr 24. doi:10.3390/ijms26094005. PMID:40362245; PMCID:PMC12071668.
  7. Lap CJ, Abrahim MS, Nassereddine S. Perspectives and challenges of small molecule inhibitor therapy for FLT3-mutated acute myeloid leukemia. Ann Hematol. 2024;103(7):2215-2229. Epub 2023 Nov 17. doi:10.1007/s00277-023-05545-3. PMID:37975931.
  8. Titah S, Guillemette A, Lewuillon C, Shaik FA, Berthon C, Goursaud L, et al. Pre-therapeutic bone marrow-resident leukemic cells in acute myeloid leukemia exhibit a distinct dysregulated calcium signature and stem-like profile reflecting minimal residual disease precursors. J Exp Clin Cancer Res. 2026;45(1):55. Epub 2026 Jan 9. doi:10.1186/s13046-025-03634-x. PMID:41508052; PMCID:PMC12911078.
  9. Hsiao TH, Wang RC, Lu TJ, Shih CH, Su YC, Tsai JR, et al. Chemoresponse of de novo acute myeloid leukemia to “7+3” induction can be predicted by c-Myc-facilitated cytogenetics. Front Pharmacol. 2021;12:649267. Epub 2021 Apr 8. doi:10.3389/fphar.2021.649267. PMID:33897436; PMCID:PMC8061304.
  10. Marrero RJ, Shastri VM, Nicolet D, Mrózek K, Walker CJ, Blum WG, et al. Cytarabine pharmacogenomics and outcomes among children and young adults with acute myeloid leukemia. JAMA Netw Open. 2025;8(6):e2516296. Epub 2025 Jun 2. doi:10.1001/jamanetworkopen.2025.16296. PMID:40549387; PMCID:PMC12186577.
  11. Mishra SV, Banerjee A, Sarkar D, Thangarathnam V, Bagal B, Hasan SK, et al. DNA-PKcs-mediated transcriptional regulation of TOP2B drives chemoresistance in acute myeloid leukemia. J Cell Sci. 2024;137(3). Epub 2024 Feb 13. doi:10.1242/jcs.261931. PMID:38240344.
  12. Werk J, Baden D, Shaforostova I, Mikesch JH, Reicherts C, Marx J, et al. Beta-blocker use and outcome after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia. Ann Hematol. 2026;105(4). Epub 2026 Mar 25. doi:10.1007/s00277-026-06962-w. PMID:41876878; PMCID:PMC13013103.
  13. Vasu S, Caligiuri MA. Targeted immunotherapy for acute myeloid leukemia. Best Pract Res Clin Haematol. 2011;24(4):533-540. Epub 2011 Nov 11. doi:10.1016/j.beha.2011.09.001. PMID:22127317; PMCID:PMC4083700.
  14. Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, et al. Mutations of epigenetics-modifying genes (DNMT3A, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2013;27(5):1044-1052. Epub 2012 Nov 8. doi:10.1038/leu.2012.317. PMID:23135354.
  15. Wang L, Song J, Xiao X, Li D, Liu T, He X. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and IDH1/2 mutation: a network meta-analysis. J Chemother. 2024;36(3):202-207. Epub 2023 Aug 20. doi:10.1080/1120009X.2023.2247200. PMID:37599456.
  16. Niscola P, Catalano G, Pasqualini G, Piccioni D, Giovannini M, Noguera NI. Venetoclax and new BCL-2 inhibitors in acute myeloid leukemia. Expert Opin Pharmacother. 2025;26(16):1725-1739. Epub 2025 Nov 2. doi:10.1080/14656566.2025.2582022. PMID:41143709.
  17. Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, et al. Phase I clinical trial of DNA methyltransferase inhibitor decitabine and PARP inhibitor talazoparib combination therapy in relapsed/refractory acute myeloid leukemia. Clin Cancer Res. 2022;28(7):1313-1322. doi:10.1158/1078-0432.CCR-21-3729. PMID:35091444; PMCID:PMC8976746.
  18. Lin H, Wang T, Wei J. Strategic innovations: tackling challenges of immunotherapy in acute myeloid leukemia. Chin J Cancer Res. 2025;37(4):490-504. doi:10.21147/j.issn.1000-9604.2025.04.02. PMID:40979658; PMCID:PMC12444347.
  19. Ma G, Wang Y, Ahmed T, Zaslav AL, Hogan L, Avila C, et al. Anti-CD19 chimeric antigen receptor targeting of CD19+ acute myeloid leukemia. Leuk Res Rep. 2018;9:42-44. Epub 2018 Mar 27. doi:10.1016/j.lrr.2018.03.002. PMID:29892548; PMCID:PMC5993359.
  20. Jin F, Wei X, Liu Y, Tang L, Ren J, Yang J, et al. Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting. Biomaterials. 2025;317:123091. Epub 2025 Jan 3. doi:10.1016/j.biomaterials.2025.123091. PMID:39778270.
  21. Chen L, Duan H, Huang C, Xu Y, Wang Z, Huang H. Humanized anti-CD33 CAR-T cells and antibody-drug conjugates for targeted therapy in acute myeloid leukemia. Front Med (Lausanne). 2026;13:1691417. Epub 2026 Jan 26. doi:10.3389/fmed.2026.1691417. PMID:41669343; PMCID:PMC12884322.
  22. Liegel J, Stroopinsky D, Cheloni G, Karagkouni D, Nahas M, Ma Y, et al. Vaccine-educated T cells and a CD123 bispecific T-cell engager for treatment of acute myeloid leukemia. Blood Adv. 2025;9(21):5585-5597. doi:10.1182/bloodadvances.2024015449. PMID:40811786; PMCID:PMC12630361.
  23. Uckun FM, Lin TL, Mims AS, Patel P, Lee C, Shahidzadeh A, et al. A clinical phase 1B study of the CD3xCD123 bispecific antibody APVO436 in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome. Cancers (Basel). 2021;13(16):4113. Epub 2021 Aug 15. doi:10.3390/cancers13164113. PMID:34439266; PMCID:PMC8394899.
  24. Zanetti LC, Tomaz V, de Souza IF, Campregher PV, Hamerschlak N, Kerbauy LN. Precision medicine with CAR cells in acute myeloid leukemia: where are we? Front Immunol. 2025;16:1653350. Epub 2025 Nov 6. doi:10.3389/fimmu.2025.1653350. PMID:41280924; PMCID:PMC12631394.
  25. Reinhardt C, Ochsenbein AF. Immune checkpoints regulate acute myeloid leukemia stem cells. Leukemia. 2025;39(6):1277-1293. Epub 2025 Apr 2. doi:10.1038/s41375-025-02566-x. PMID:40175626; PMCID:PMC12133569.
  26. Zhou HS, Su YF, Wang J, Hu YL, Wang A, Xu L, et al. Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia. Front Immunol. 2025;16:1533467. Epub 2025 Apr 17. doi:10.3389/fimmu.2025.1533467. PMID:40313949; PMCID:PMC12043577.
  27. Zha C, Yang X, Yang J, Zhang Y, Huang R. Immunosuppressive microenvironment in acute myeloid leukemia: overview, therapeutic targets and corresponding strategies. Ann Hematol. 2024;103(12):4883-4899. Epub 2024 Nov 28. doi:10.1007/s00277-024-06117-9. PMID:39607487.
  28. Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, et al. Different features of acute myeloid leukemia stem cell quantification in intensively treated patients. Haematologica. 2025;110(12):2942-2953. Epub 2025 Apr 30. doi:10.3324/haematol.2024.287090. PMID:40304060; PMCID:PMC12666270.
  29. Boila LD, Ghosh S, Bandyopadhyay SK, Jin L, Murison A, Zeng AGX, et al. KDM6 demethylases integrate DNA repair gene regulation and loss of KDM6A sensitizes human acute myeloid leukemia to PARP and BCL2 inhibition. Leukemia. 2023;37(4):751-764. Epub 2023 Jan 31. doi:10.1038/s41375-023-01833-z. PMID:36720973.
  30. Damiani D, Tiribelli M. ABCG2 in acute myeloid leukemia: old and new perspectives. Int J Mol Sci. 2023;24(8):7147. Epub 2023 Apr 12. doi:10.3390/ijms24087147. PMID:37108308; PMCID:PMC10138346.
  31. Gu H, Chen C, Hou ZS, He XD, Xie S, Ni J, et al. PI3K? maintains the self-renewal of acute myeloid leukemia stem cells by regulating the pentose phosphate pathway. Blood. 2024;143(19):1965-1979. doi:10.1182/blood.2023022202. PMID:38271660; PMCID:PMC11103183.
  32. Peroni E, Randi ML, Rosato A, Cagnin S. Acute myeloid leukemia: from NGS through scRNA-seq to CAR-T, dissect cancer heterogeneity and tailor the treatment. J Exp Clin Cancer Res. 2023;42(1):259. Epub 2023 Oct 6. doi:10.1186/s13046-023-02841-8. PMID:37803464; PMCID:PMC10557350.
  33. Cauchy P, James SR, Zacarias-Cabeza J, Ptasinska A, Imperato MR, Assi SA, et al. Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature. Cell Rep. 2015;12(5):821-836. Epub 2015 Jul 23. doi:10.1016/j.celrep.2015.06.069. PMID:26212328; PMCID:PMC4726916.
  34. Kawashima N, Ishikawa Y, Kim JH, Ushijima Y, Akashi A, Yamaguchi Y, et al. Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nat Commun. 2022;13(1):1624. Epub 2022 Mar 25. doi:10.1038/s41467-022-29304-6. PMID:35338146; PMCID:PMC8956585.
  35. Fu YH, Ng KM, Tseng CY, Huang AC, Tu CH, Chen WC, et al. Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models. Cell Death Discov. 2026;12(1):98. Epub 2026 Feb 17. doi:10.1038/s41420-026-02957-8. PMID:41702887; PMCID:PMC12920922.
  36. Liao X, Dai W, Xu X, Cai D, Tan M, Wang Z, et al. Marrow leptin-LEPR signaling rewires mitochondrial oxidative metabolism to confer chemoresistance in acute myeloid leukemia. Cell Death Dis. 2026;17(1). Epub 2026 Feb 23. doi:10.1038/s41419-026-08528-0. PMID:41730833; PMCID:PMC12966444.
  37. Pan M, Jiao C, Sun M, Jin D, Wang Y, Wu H, et al. Venetoclax synergizes with Wnt/?-catenin inhibitor C-82 in acute myeloid leukemia by increasing the degradation of Mcl-1 protein. Cancer Cell Int. 2025;25(1):197. Epub 2025 May 29. doi:10.1186/s12935-025-03825-8. PMID:40442688; PMCID:PMC12121061.
  38. Costa RGA, Silva SLR, Dias I, Oliveira MS, Rodrigues A, Dias RB, et al. Emerging drugs targeting cellular redox homeostasis to eliminate acute myeloid leukemia stem cells. Redox Biol. 2023;62:102692. Epub 2023 Apr 2. doi:10.1016/j.redox.2023.102692. PMID:37031536; PMCID:PMC10119960.
  39. Aroua N, Boet E, Ghisi M, Nicolau-Travers ML, Saland E, Gwilliam R, et al. Extracellular ATP and CD39 activate cAMP-mediated mitochondrial stress response to promote cytarabine resistance in acute myeloid leukemia. Cancer Discov. 2020;10(10):1544-1565. Epub 2020 Jul 8. doi:10.1158/2159-8290.CD-19-1008. PMID:32641297.
  40. Guarnera L, Santinelli E, Galossi E, Cristiano A, Fabiani E, Falconi G, et al. Microenvironment in acute myeloid leukemia: focus on senescence mechanisms, therapeutic interactions, and future directions. Exp Hematol. 2024;129:104118. Epub 2023 Sep 22. doi:10.1016/j.exphem.2023.09.005. PMID:37741607.
  41. Gabellier L, Bosetta E, Heiblig M, Sarry JE. Metabolism and therapeutic response in acute myeloid leukemia with IDH1/2 mutations. Trends Cancer. 2025;11(5):475-490. Epub 2025 Feb 17. doi:10.1016/j.trecan.2025.01.011. PMID:39955197.
  42. Liu W, Ming X, Wu J, Yan S, Su S, Zheng R, et al. AML-derived bone mesenchymal stem cell exosomal METTL14 promotes AML cell growth and glycolysis by HOXA3/WNT7B axis. Cell Biol Toxicol. 2026;42(1):27. Epub 2026 Jan 29. doi:10.1007/s10565-026-10143-w. PMID:41609866; PMCID:PMC12894161.
  43. Lam K, Kim YJ, Tan EL, Ong CM, Liu AZ, Zhou FJ, et al. The proteostasis network is a therapeutic target in acute myeloid leukemia. Blood. 2026;147(5):557-572. doi:10.1182/blood.2024026749. PMID:41111393; PMCID:PMC12883865.
  44. Tang Y, Li J, Ye W, Du Y, Zhang Y, Ye Y, et al. Overcoming therapeutic challenges in acute myeloid leukemia: active targeting strategies by nano-drug delivery systems. J Transl Med. 2026;24(1). Epub 2026 Feb 7. doi:10.1186/s12967-026-07792-0. PMID:41654885; PMCID:PMC12977839.
  45. Fathima S, Rokach L, Ghosoun N, Rezasoltani M, Ilyas R, Alsugair A, et al. CPX-351 versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients. Blood Cancer J. 2026 Apr 6 [Epub ahead of print]. doi:10.1038/s41408-026-01495-x. PMID:41942467.
  46. Cruz-Rodriguez N. Exploiting metabolic dependencies in acute myeloid leukemia: DHODH inhibition meets lipid and cholesterol metabolism. Haematologica. 2026 Feb 26 [Epub ahead of print]. doi:10.3324/haematol.2026.300677. PMID:41742882.
  47. Da Ros A, Peloso A, Longo G, Benetton M, Indio V, Cairo S, et al. Advancing precision therapy in pediatric acute myeloid leukemia through PDX models and mitochondrial targeting. Blood Adv. 2026;10(7):2153-2167. doi:10.1182/bloodadvances.2025018002. PMID:41576348; PMCID:PMC13049648.
  48. Parfenova EN, Vrdoljak N, Mosca D, Aristizabal-Henao JJ, Kiebish MA, Minden MD, et al. Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate acute myeloid leukemia cells. Blood. 2026 Feb 26 [Epub ahead of print]. doi:10.1182/blood.2025031202. PMID:41746867.
  49. Wu X, Zhang J. Multi-omics approaches to understanding therapy resistance in acute lymphoblastic leukemia. Lymphatics. 2026;4(1):8. doi:10.3390/lymphatics4010008.
  50. Chen P, Gao G, Xu Y, Jia P, Li Y, Li Y, et al. Novel gene signature reveals prognostic model in acute lymphoblastic leukemia. Front Cell Dev Biol. 2022;10:1036312. Epub 2022 Nov 3. doi:10.3389/fcell.2022.1036312. PMID:36407095; PMCID:PMC9669305.
  51. Bawek S, Gurusinghe S, Burwinkel M, Przespolewski A. Updates in novel immunotherapeutic strategies for relapsed/refractory AML. Front Oncol. 2024;14:1374963. Epub 2024 Dec 4. doi:10.3389/fonc.2024.1374963. PMID:39697225; PMCID:PMC11652486.
  52. Tang J, Ye X, Xu Z, Min T, Tian Z, Ma L, et al. Epigenetic mechanisms of drug resistance in acute myeloid leukemia: advances in small-molecule targeted therapy. Front Pharmacol. 2025;16:1672524. Epub 2025 Oct 20. doi:10.3389/fphar.2025.1672524. PMID:41199817; PMCID:PMC12587329.
  53. Zhu Y, Liu J, Qiu F, You Z, Liu Z, Zeng J, et al. The tumor microenvironment in leukemia: molecular pathways of immune evasion. Front Immunol. 2026;17:1743920. Epub 2026 Feb 6. doi:10.3389/fimmu.2026.1743920. PMID:41727472; PMCID:PMC12920481.
  54. Pirouzbakht M, Hamzeh S, Soleimani Samarkhazan H. Beyond single biomarkers: multi-omics strategies to predict immunotherapy outcomes in blood cancers. Clin Exp Med. 2025;25(1):355. Epub 2025 Nov 6. doi:10.1007/s10238-025-01902-w. PMID:41193778; PMCID:PMC12589271.
  55. Zhuang J, Li Y, Zhang Y, Huang Y, Han Y, Lin N, et al. Mechanisms, treatment strategies and predictive biomarkers of drug resistance in acute myeloid leukemia. Mutat Res Rev Mutat Res. 2025;797:108578. Epub 2025 Dec 8. doi:10.1016/j.mrrev.2025.108578. PMID:41371488.
  56. Rautenberg C, Stelljes M, Bug G, Holtick U, Jost E, Jennrich S, et al. Pretransplantation hypomethylating agents and venetoclax in acute myeloid leukemia patients: a real-world analysis from the cooperative transplant study group. Transplant Cell Ther. 2025 Dec 15 [Epub ahead of print]. doi:10.1016/j.jtct.2025.12.943. PMID:41407010.
  57. Zheng T, Chen P, Xu Y, Jia P, Li Y, Li Y, et al. Comprehensive analysis of thirteen-gene panel with prognostic value in multiple myeloma. Cancer Biomark. 2023;38(4):583-593. doi:10.3233/CBM-230115. PMID:37980648.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership